How Vertical Integration Might Affect Biosimilar Availability

Jonathan Ogurchak, PharmD, CSP, sits down with Specialty Pharmacy Times to discuss how vertical integration might affect biosimilar availability in specialty pharmacy during the NASP Annual Meeting in Washington, DC.

Jonathan Ogurchak, PharmD, CSP, sits down with Specialty Pharmacy Times to discuss how vertical integration might affect biosimilar availability in specialty pharmacy during the NASP Annual Meeting in Washington, DC.

Jonathan Ogurchak, PharmD, CSP, sits down with Specialty Pharmacy Times to discuss how vertical integration might affect biosimilar availability in specialty pharmacy during the NASP Annual Meeting in Washington, DC. JO: So, biosimilars, historically, have had a difficult time entering the marketplace just based on approvals, based on patent litigation, based on everything from acceptance. Now, the advent of vertical integration is really helping to better define where a place for biosimilars is within a particular segment of the marketplace. So, the potential exists not only due to vertical integration but just due to a broadening of biosimilar commercial availability that it’s going to help and the vertical integration piece is helping to better define what that cost savings is, what the best utilization processes are for these types of drugs and really help to drive some of the outcomes for making a switch to a biosimilar product.